The Food and Drug Administration has fast-tracked three psychedelic medicines for review, issuing priority vouchers to companies studying psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone, a compound related to MDMA, for post-traumatic stress disorder, in a development that could put the first FDA-approved psychedelic medicines on
